RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma

BACKGROUND: Neoadjuvant chemotherapy – often using docetaxel in various combinatorial regimens – is a standard treatment choice for advanced oesophageal squamous cell carcinoma (ESCC) in Japan. However, no useful markers exist that predict docetaxel’s effects on ESCC. Ribophorin II (RPN2) silencing,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Kurashige, J, Watanabe, M, Iwatsuki, M, Kinoshita, K, Saito, S, Nagai, Y, Ishimoto, T, Baba, Y, Mimori, K, Baba, H
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494434/
https://ncbi.nlm.nih.gov/pubmed/22955852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.396
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars